Elsevier

Blood Reviews

Volume 19, Issue 2, March 2005, Pages 111-123
Blood Reviews

REVIEW
Platelet function analysis

https://doi.org/10.1016/j.blre.2004.05.002Get rights and content

Abstract

Since the last guidelines for BCSH platelet function testing were written in the late 1980s, many new tests have become available. Previously most platelet function tests were traditionally utilized to aid in the diagnosis and management of patients with platelet and haemostatic disorders. Most traditional tests were also largely restricted to the specialized laboratory or centre. However, nowadays there is also much renewed interest in monitoring the efficacy of anti-platelet therapy and measuring platelet hyper-function. A number of dedicated platelet function instruments have now become available that are much simpler to use and are beginning to be utilized as point of care instruments. These can now provide measurement of platelet function within whole blood without the requirement of sample processing. Some are also beginning to be incorporated into routine clinical use and can be utilized as not only as general screening tests of platelet function but to monitor anti-platelet therapy and to potentially assess both risk of bleeding and/or thrombosis. Modern flow cytometric-based platelet function analysis now also provides a wide variety of specific tests that can assess different aspects of platelet biology that are useful for diagnostic purposes. This review will highlight some of these of new tests/instruments and discuss their potential utility both within the haemostasis laboratory but also as potential point of care instruments.

Introduction

Human platelets are small and discoid in shape, with dimensions of approximately 2.0–4.0 by 0.5 μm, and a mean volume of 7–11 fl.1 They are the second most numerous corpuscle in the blood normally circulating at between 150–450 × 109/l. Platelets are anucleated cells derived from megakaryocytes and typically circulate for 10 days.1 Their shape and small size enables the platelets to be pushed to the edge of vessels, placing them in the optimum location required to constantly survey the integrity of the vasculature. Platelets are also surprisingly multifunctional and are involved in many pathophysiological processes including haemostasis and thrombosis, clot retraction, vessel constriction and repair, inflammation including promotion of atherosclerosis, host defence and even tumour growth/metastasis (Fig. 1). Although, any test(s) of platelets could therefore potentially measure any one or more of these vital processes, the majority of available tests focus only on those function(s) involved directly in haemostasis.

Upon vessel wall damage, platelets undergo a highly regulated set of functional responses including adhesion, spreading, release reactions, aggregation, exposure of a procoagulant surface, microparticle formation and clot retraction (Fig. 2). All of these platelet responses function to rapidly form a haemostatic plug that occludes the site of damage to prevent blood loss.[2], [3] When there is a defect in any of these functions and/or platelet number, haemostasis is usually impaired and there may be an associated increased risk of bleeding. In contrast, a marked increase in platelet number or reactivity can lead to inappropriate thrombus formation. Arterial thrombi can also develop within atherosclerotic lesions resulting in stroke and myocardial infarction, two of the major causes of morbidity and mortality in the western world.4 Anti-platelet therapy can therefore be beneficial in the treatment and prophylaxis of arterial thrombotic conditions, but must be carefully administered without increasing the risk of bleeding to an unacceptable level.1

The main use of platelet function tests has been traditionally to identify the potential causes of abnormal bleeding,5 to monitor pro-haemostatic therapy in patients with a high risk of bleeding and to ensure normal platelet function either prior to or during surgery.[6], [7] However, they are increasingly being utilised to monitor the efficacy of anti-platelet therapy and to potentially identify platelet hyperfunction to predict thrombosis.[6], [8] For a full list of potential clinical uses of platelet function tests see Table 1.

Section snippets

History of platelet function testing

Platelets were first described by the remarkably early observations of Bizzozero in the late 1800s.9 Not only did he identify platelets as distinct corpuscles within human blood but he observed them forming thrombi within damaged areas of vessel wall using real-time microscopy. Today, modern imaging methods are utilised to study in detail the same real time interactions of platelets with the vessel wall and dynamics of thrombus formation.10

Table 2 illustrates a list of traditional tests of

Quality control, blood sampling and anticoagulation

Platelet function testing presents many challenges in ensuring that accurate and meaningful results are obtained. Firstly, unlike with coagulation tests, there are no widely available internal or external quality control materials available. Most assays are performed on fresh blood and so many laboratories either establish normal ranges using control volunteer blood and/or assay known normal samples in parallel to ensure that each test/reagent is viable. Many platelet function tests such as

Initial approach to diagnosing platelet dysfunction

When investigating a suspected bleeding disorder, it is essential to obtain a detailed clinical and family history and perform a physical examination before choosing the laboratory tests to be undertaken.[3], [27] In particular a recent drug history is critically important and patients should be advised to discontinue where possible any drug that could interfere with platelet function. Some drugs may cause a transient haemostatic defect, so repeat or deferred testing is often necessary. Other

The bleeding time

The bleeding time (BT), developed by Duke in 1910,34 was the first in vivo test of platelet function and was still regarded as the most useful test of platelet function until the early 1990s.12 The bleeding time is the time taken for bleeding to stop after an incision is made into the skin, usually into the anterior surface of forearm (Fig. 3). The test has been refined and standardised particularly with the use of a sphygmomanometer cuff and a spring-loaded template device to make standard

Platelet aggregation

Platelet aggregometry was developed in the early 1960s and soon became regarded as the “gold standard” of platelet function testing.37 This is still the most widely used test for identifying and diagnosing platelet function defects and can be performed within commercially available multi-channel aggregometers. Whole blood aggregometers using impedance technology are also available and are sometimes combined with luminometry to simultaneously measure dense granular ADP release. However, in most

The platelet function analyser – PFA-100®

The PFA-100® is a relatively simple bench top instrument that simulates high shear platelet function within disposable test cartridges (Fig. 4).[17], [38], [39] Citrated blood is aspirated under constant negative pressure from the sample reservoir through a capillary and a microscopic aperture (147 μm) cut into a membrane. The membrane is coated with either collagen/epinephrine (CEPI) or collagen/ADP (CADP). The presence of these platelet activators and the high shear rates (5000–6000 s−1)

The cone and plate(let) analyser

Another test that has recently been developed is based upon the adhesion of platelets to the extracellular matrix using whole blood exposed to high shear. The original The cone and plate(let) analyser (CPA) device tested whole blood platelet adhesion and aggregation on a plate coated with extracellular matrix (ECM).[19], [51] The CPA has now been developed into a fully automated commercial instrument called the IMPACT® (Diamed, Switzerland) (see Fig. 5) and now utilises polystyrene plates

The ultegra rapid platelet function assay – RPFA®

The Ultegra-RPFA® (Accumetrics, Inc, San Diego, California) is a turbidimetric based optical detection system (see Fig. 6) that measures platelet induced aggregation as an increase in light transmittance.[23], [52] This modified platelet aggregometry device was originally developed as a near patient testing instrument in order to provide a simple and rapid functional means of monitoring anti-Gp IIb/IIIa therapy with various anti-platelet drugs (e.g. abciximab).52 The disposable cartridges

Hemostasis analysis system®

Hemodyne have developed and refined a Hemostasis Analysis System® (HAS) over the last 7 years (Fig. 7). This instrument is based upon the original technique developed by Carr.21 The HAS measures platelet contractile force (PCF®), clot elastic modulus (CEM®) and thrombin generation time (TGT®) in a sample (700 μl) of clotting whole blood. PCF® is the force generated by platelets during clot retraction. In this instrument a small sample of whole blood is trapped between two parallel surfaces.

Plateletworks®

Platelets within whole blood, when stimulated by agonists forms aggregates with a reduction in the number of free platelets. By counting the number of platelets in a control sample (usually EDTA) and within a sample that has been activated with a classical platelet agonist it is possible to assess the degree of platelet aggregation that can occur in a given sample. The Plateletworks® aggregation kits (Helena Biosciences) are simply based upon comparing platelet counts within a baseline EDTA

Flow cytometry

There is no doubt that one of the biggest advances in platelet function analysis has been the application of flow cytometry.[25], [62] This technique however, requires access to an expensive instrument and specialised training to perform. A number of largely research applications continue to evolve into clinically useful tests particularly as many of the reagents, antibodies and dyes are now commercially available.11 A list of currently available diagnostic flow cytometry assays are shown in

Conclusions

The last guidelines for platelet function testing were written in the late 1980s.12 Given the advances in this field and the introduction of potentially useful additions to our existing portfolio of platelet function tests, work is currently in progress to rewrite these guidelines. Nevertheless, the incorporation of new platelet function tests into the routine laboratory has already begun and a number of new approaches have been suggested.[5], [29], [40] Flow cytometric-based platelet function

Acknowledgements

The author thank Dr. David Keeling and Professor Steve Watson for carefully reading the manuscript. I also thank Professor Sam Machin for providing Fig. 3.

References (75)

  • B. Jilma

    Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction

    J. Lab. Clin. Med

    (2001)
  • E. Fressinaud et al.

    Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases

    Blood

    (1998)
  • M. Fattorutto et al.

    Does the platelet function analyser (PFA-100) predict blood loss after cardiopulmonary bypass?

    Br. J. Anaesth

    (2003)
  • K. Andersen et al.

    Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease

    Thromb. Res

    (2002)
  • L. Macchi et al.

    Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate

    Thromb. Res

    (2002)
  • P.A. Gum et al.

    Profile and prevalence of aspirin resistance in patients with cardiovascular disease

    Am. J. Cardiol

    (2001)
  • D. Varon et al.

    A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions

    Thromb. Res

    (1997)
  • J.C. Wang et al.

    Incidence of aspirin nonresponsiveness using the Ultegra rapid platelet function assay – ASA

    Am. J. Cardiol

    (2003)
  • A.I. Malinin et al.

    Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease

    Eur. J. Pharmacol

    (2003)
  • M.E. Carr et al.

    Onset of force development as a marker of thrombin generation in whole blood: the thrombin generation time (TGT)

    J. Thromb. Haemost

    (2003)
  • P.E. Greilich et al.

    Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease

    Am. J. Med. Sci

    (1994)
  • M.E. Carr

    Diabetes mellitus: a hypercoagulable state

    J. Diabetes Complicat

    (2001)
  • N.S. Nicholson et al.

    Assessment of platelet function assays

    Am. Heart J

    (1998)
  • J.E. Mobley et al.

    Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization

    Am. J. Cardiol

    (2004)
  • T.L. Lindahl et al.

    Studies of the platelet fibrinogen receptor in Glanzmann patients and uremic patients

    Thromb. Res

    (1992)
  • J.P. McRedmond et al.

    Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes

    Mol. Cell Proteomics

    (2004)
  • D.V. Gnatenko et al.

    Transcript profiling of human platelets using microarray and serial analysis of gene expression

    Blood

    (2003)
  • A. Garcia et al.

    Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins

    Blood

    (2004)
  • P.B. Maguire et al.

    Platelet proteomics

    J. Thromb. Haemost

    (2003)
  • A.D. Michelson

    Platelets

    (2002)
  • G.M. Rodgers

    Overview of platelet physiology and laboratory evaluation of platelet function

    Clin. Obstet. Gynecol

    (1999)
  • Z.M. Ruggeri

    Platelets in atherothrombosis

    Nat. Med

    (2002)
  • P. Thiagarajan et al.

    In vitro assays for evaluating platelet function

  • S. Tsiara et al.

    Platelets as predictors of vascular risk: is there a practical index of platelet activity

    Clin. Appl. Thromb. Hemost

    (2003)
  • G. de Gaetano

    A new blood corpuscle: an impossible interview with Giulio Bizzozero

    Thromb. Haemost

    (2001)
  • P. Harrison

    Progress in the assessment of platelet function

    Br. J. Haematol

    (2000)
  • Guidelines on platelet function testing. The British Society for Haematology BCSH Haemostasis and Thrombosis Task...
  • Cited by (0)

    View full text